Business context and reporting period
OrthoPediatrics Corp. (Nasdaq: KIDS) designs and sells orthopedic implants, instruments and specialized braces for children. This Form 10-K covers the fiscal year ended December 31, 2022; it is an annual report, not a standalone fourth-quarter report. The company reported one operating segment and served customers in the U.S. and more than 70 other countries.
In 2022, OrthoPediatrics acquired MD Orthopaedics, a clubfoot-products business, and Pega Medical, a trauma and deformity-device company. Management estimates its currently served market opportunity at $3.9 billion globally, including more than $1.7 billion in the U.S.
Financial performance and position
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $122.3 million | $98.0 million |
| Gross profit / margin | $90.7 million / 74% | $73.4 million / 75% |
| Operating loss | $25.4 million | $18.0 million |
| Net income (loss) | $1.3 million | $(16.3) million |
| Diluted earnings (loss) per share | $0.06 | $(0.84) |
| Cash used in operating activities | $21.8 million | $13.1 million |
| Cash and restricted cash | $10.5 million | $9.0 million |
| Short-term investments | $109.3 million | $45.9 million |
At year-end 2022, total assets were $427.7 million, total liabilities $49.1 million and stockholders’ equity $378.6 million. The company had $0.9 million of mortgage debt and no borrowings under its $50 million revolving facility. Current liabilities were $30.9 million.
Revenue rose 25%. U.S. revenue increased to $92.4 million (76% of total) and international revenue to $29.9 million (24%). By product category, trauma and deformity revenue was $85.1 million, scoliosis $33.4 million, and sports medicine/other $3.8 million. The filing does not provide a consolidated operating cash-flow margin or a formal quarterly financial breakdown in the supplied text.
Material changes and unusual items
- Revenue growth reflected recovery in domestic and global markets and $11.2 million of sales from the MD Ortho and Pega acquisitions. Higher respiratory-illness hospitalizations reduced elective procedure volume; foreign-currency conversion also weighed on international revenue.
- Net income was supported by $25.9 million of income from a fair-value reduction in ApiFix contingent consideration and a $4.9 million income-tax benefit. Despite the reported profit, the company had a $25.4 million operating loss and used $21.8 million of cash in operations.
- The company recorded a $3.6 million impairment of the ApiFix trademark, citing lower-than-expected forecast revenue. Gross margin eased one percentage point, partly due to more international instrument-set sales at cost and $1.1 million in Firefly minimum-performance fees.
- Operating expenses increased, including general and administrative costs (+29%) and research and development costs (+45%), reflecting growth, acquisition-related expenses and investment in product development.
- An August 2022 public offering of common stock and pre-funded warrants generated approximately $139.3 million net proceeds. The company repaid $31 million drawn on its revolving facility; the warrants were exercised in September. Year-end common shares outstanding were 22.9 million, versus 19.7 million a year earlier.
- Investing cash outflow was $113.4 million, including acquisition spending, purchases of short-term investments and $10.0 million of property and equipment, primarily instrument sets.
Outlook, risks and contingencies
Management said available cash, investments, revolving-facility capacity, product receipts and offering proceeds were expected to cover anticipated cash requirements for at least 12 months. It also expects near-term investment and losses as it expands products and consigned instrument sets; the filing gives no numerical revenue or earnings guidance.
Planned development milestones included a 510(k) submission for the Pediatric Nailing Platform | Tibia in the first half of 2023, with beta launch targeted for 2023 and full launch for 2024, and a 2023 beta launch target for the RESPONSE Rib and Pelvic System. The ERP system upgrade was expected to be completed in the second quarter of 2023.
- Key business risks include procedure disruption from COVID-19, RSV and hospital capacity constraints; inflation, interest rates and supply-chain pressures; reliance on independent sales agencies, distributors and third-party manufacturers; and the cost and utilization risk of consigned inventory.
- Regulatory compliance and product clearances remain important, including EU MDR certification and U.K. market requirements. The ApiFix device is subject to HDE reporting and institutional review board requirements.
- OrthoPediatrics disclosed ongoing IMED Surgical software/patent ownership litigation and Wishbone patent litigation. Management said it intends to defend the claims; adverse outcomes could affect operations or finances. A $1.25 million escrow balance related to the Vilex sale remained restricted in connection with the IMED matter.
- Other exposures include product-liability claims, reimbursement changes, acquisition integration and contingent-payment estimates, foreign exchange, cybersecurity and ERP implementation. The company reported no material legal proceedings beyond those described in the filing.
- The auditor issued an unmodified opinion on the consolidated financial statements and highlighted ApiFix trademark impairment as a critical audit matter. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not engaged to attest to internal-control effectiveness.
Most important facts for investors to verify
- How much of FY2022 profitability depended on the ApiFix fair-value gain and tax benefit, and whether core operating performance is improving.
- Whether operating cash use and inventory growth moderate as acquisitions are integrated and instrument sets are deployed.
- Revenue, margins and procedure volumes from MD Ortho and Pega, including the effect of RSV and foreign exchange.
- Progress on planned product launches, regulatory certifications and the ERP upgrade.
- Final acquisition valuations and ApiFix contingent or installment payments, as well as the status and potential exposure of disclosed litigation.
- Liquidity and capital needs after the offering, and the terms and maturity of the Squadron revolving facility, which matures no later than January 1, 2024.